Esophageal Cancer Clinical Trial

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

Summary

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Adequate organ and marrow function

Exclusion Criteria:

History of trauma or major surgery within 28 days prior to the first dose of study treatment.
Prior treatment with an anti-TIGIT antibody.
Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
Discontinued prior immunotherapy for immune related adverse events with a high severity.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study is for people with:

Esophageal Cancer

Phase:

Phase 1

Estimated Enrollment:

160

Study ID:

NCT04772989

Recruitment Status:

Recruiting

Sponsor:

Arcus Biosciences, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 19 Locations for this study

See Locations Near You

Mayo Clinic Arizona - Mayo Clinic Hospital
Phoenix Arizona, 85054, United States
University of California, Los Angeles
Los Angeles California, 90095, United States
University of Colorado - Cancer Center - PPDS
Aurora Colorado, 80045, United States
Mayo Clinic Jacksonville - PPDS
Jacksonville Florida, 32224, United States
AdventHealth Orlando
Orlando Florida, 43210, United States
Augusta Oncology Associates - Wheeler Road
Augusta Georgia, 30909, United States
Goshen Health System
Goshen Indiana, 46526, United States
Holden Comprehensive Cancer Center
Iowa City Iowa, 52242, United States
Norton Cancer Institute-Downtown
Louisville Kentucky, 40202, United States
Henry Ford Health System
Novi Michigan, 48377, United States
Mayo Clinic - PPDS
Rochester Minnesota, 55905, United States
Columbia University Medical Center
New York New York, 10032, United States
Ohio State University
Columbus Ohio, 43210, United States
University of Oklahoma Peggy and Charles Stephenson Cancer Center
Oklahoma City Oklahoma, 73104, United States
University of Pittsburgh Medical Center
Pittsburgh Pennsylvania, 15240, United States
Tennessee Onocology - Nashville
Nashville Tennessee, 37205, United States
START South Texas Accelerated Research Therapeutics - San Antonio
San Antonio Texas, 78229, United States
START South Texas Accelerated Research Therapeutics - Mountain Region
West Valley City Utah, 84119, United States
Virginia Cancer Specialists
Fairfax Virginia, 22033, United States
University of Wisconsin - Madison
Madison Wisconsin, 53792, United States

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 1

Estimated Enrollment:

160

Study ID:

NCT04772989

Recruitment Status:

Recruiting

Sponsor:


Arcus Biosciences, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.